Recombinant human erythropoietin treatment protects the cardio-renal axis in a model of moderate chronic renal failure

Chronic kidney disease (CKD) patients develop anemia because of the low kidney erythropoietin (EPO) production, thus promoting cardiovascular complications. The degree of renal insufficiency might determine the moment to start recombinant human erythropoietin (rhEPO) therapy, but the molecular basis...

Full description

Bibliographic Details
Main Author: Teixeira, Ana Margarida (author)
Other Authors: Garrido, Patrícia (author), Santos, Paulo (author), Alves, Rui (author), Parada, Belmiro (author), Costa, Elísio (author), Almeida, Anabela (author), Teixeira-Lemos, Edite (author), Sereno, José (author), Pinto, Rui (author), Belo, Luís (author), Santos-Silva, Alice (author), Teixeira, Frederico (author), Reis, Flávio (author)
Format: article
Language:eng
Published: 2011
Subjects:
Moderate chronic renal failure
rhEPO treatment
Cardio-renal protection
Proliferation
Hypertroph
Apoptosis
Online Access:http://hdl.handle.net/10400.14/4437
Country:Portugal
Oai:oai:repositorio.ucp.pt:10400.14/4437

Internet

http://hdl.handle.net/10400.14/4437

Similar Items